Drug intelligence / Profile preview

mitozolomide

Development stage: Discontinued
Lead developer: May & Baker
Modality: Small Molecules
Administration: Oral

Overview

Mitozolomide is an imidazotetrazine derivative and an alkylating agent that was developed as an experimental antineoplastic (anticancer) drug. It acts via methylation of DNA, leading to DNA damage and cell death through apoptosis, in a mechanism similar to related agents like temozolomide. Mitozolomide was evaluated in the 1980s and 1990s but was never approved for clinical use due to high toxicity and lack of efficacy compared to successors. Its major activity involves methyl group transfer to guanine residues in DNA, resulting in cytotoxicity in rapidly dividing tumor cells.

Targets

DNA

Beyond the preview

Go deeper on mitozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitozolomide.

Explore the full profile